Emily Bodnar
Stock Analyst at HC Wainwright & Co.
(1.76)
# 3,391
Out of 5,115 analysts
346
Total ratings
26.32%
Success rate
-7.95%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Emily Bodnar
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RAPT RAPT Therapeutics | Downgrades: Neutral | $58 | $57.68 | +0.55% | 4 | Jan 20, 2026 | |
| NVCR NovoCure | Maintains: Buy | $42 → $39 | $12.40 | +214.52% | 20 | Jan 13, 2026 | |
| VTYX Ventyx Biosciences | Downgrades: Neutral | $14 | $13.95 | +0.36% | 17 | Jan 8, 2026 | |
| AGIO Agios Pharmaceuticals | Maintains: Buy | $48 → $62 | $27.44 | +125.95% | 4 | Dec 24, 2025 | |
| VTVT vTv Therapeutics | Maintains: Buy | $36 → $47 | $35.98 | +30.63% | 3 | Dec 19, 2025 | |
| RCUS Arcus Biosciences | Maintains: Buy | $28 → $32 | $21.04 | +52.09% | 7 | Dec 12, 2025 | |
| OLMA Olema Pharmaceuticals | Maintains: Buy | $36 → $45 | $25.72 | +74.96% | 23 | Dec 11, 2025 | |
| ACRV Acrivon Therapeutics | Reiterates: Buy | $19 | $1.79 | +961.45% | 13 | Nov 25, 2025 | |
| ANAB AnaptysBio | Maintains: Buy | $52 → $51 | $47.41 | +7.57% | 13 | Nov 24, 2025 | |
| ARTV Artiva Biotherapeutics | Maintains: Buy | $12 → $15 | $3.89 | +285.60% | 2 | Nov 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $11 → $9 | $4.43 | +103.16% | 12 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $4 → $5 | $2.61 | +91.57% | 13 | Nov 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $12 | $1.00 | +1,100.00% | 1 | Oct 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $60 | $29.43 | +103.87% | 1 | Oct 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $0.29 | - | 14 | Sep 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $23 | $2.84 | +709.86% | 20 | Sep 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $32 → $40 | $4.30 | +830.23% | 15 | Aug 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $35 | $11.78 | +197.11% | 14 | Aug 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 → $8 | $0.54 | +1,394.77% | 25 | Aug 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 → $9 | $4.39 | +105.01% | 2 | Jul 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $40 → $20 | $1.48 | +1,251.35% | 10 | Jul 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $36 | $10.85 | +231.80% | 9 | Jul 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $115 | $68.31 | +68.35% | 13 | Jun 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $560 → $280 | $9.49 | +2,850.47% | 17 | Apr 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $8 | $2.42 | +230.58% | 6 | Apr 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $30 | $2.66 | +1,027.82% | 7 | Mar 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $18 | $2.22 | +710.81% | 15 | Mar 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $183 | $3.32 | +5,400.30% | 12 | Mar 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $7 | $0.57 | +1,138.94% | 14 | Mar 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $1.37 | - | 5 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $33 | $0.60 | +5,363.58% | 14 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $3.15 | - | 1 | Apr 25, 2024 |
RAPT Therapeutics
Jan 20, 2026
Downgrades: Neutral
Price Target: $58
Current: $57.68
Upside: +0.55%
NovoCure
Jan 13, 2026
Maintains: Buy
Price Target: $42 → $39
Current: $12.40
Upside: +214.52%
Ventyx Biosciences
Jan 8, 2026
Downgrades: Neutral
Price Target: $14
Current: $13.95
Upside: +0.36%
Agios Pharmaceuticals
Dec 24, 2025
Maintains: Buy
Price Target: $48 → $62
Current: $27.44
Upside: +125.95%
vTv Therapeutics
Dec 19, 2025
Maintains: Buy
Price Target: $36 → $47
Current: $35.98
Upside: +30.63%
Arcus Biosciences
Dec 12, 2025
Maintains: Buy
Price Target: $28 → $32
Current: $21.04
Upside: +52.09%
Olema Pharmaceuticals
Dec 11, 2025
Maintains: Buy
Price Target: $36 → $45
Current: $25.72
Upside: +74.96%
Acrivon Therapeutics
Nov 25, 2025
Reiterates: Buy
Price Target: $19
Current: $1.79
Upside: +961.45%
AnaptysBio
Nov 24, 2025
Maintains: Buy
Price Target: $52 → $51
Current: $47.41
Upside: +7.57%
Artiva Biotherapeutics
Nov 12, 2025
Maintains: Buy
Price Target: $12 → $15
Current: $3.89
Upside: +285.60%
Nov 7, 2025
Maintains: Buy
Price Target: $11 → $9
Current: $4.43
Upside: +103.16%
Nov 6, 2025
Maintains: Buy
Price Target: $4 → $5
Current: $2.61
Upside: +91.57%
Oct 14, 2025
Initiates: Buy
Price Target: $12
Current: $1.00
Upside: +1,100.00%
Oct 6, 2025
Assumes: Buy
Price Target: $60
Current: $29.43
Upside: +103.87%
Sep 29, 2025
Downgrades: Neutral
Price Target: n/a
Current: $0.29
Upside: -
Sep 10, 2025
Reiterates: Buy
Price Target: $23
Current: $2.84
Upside: +709.86%
Aug 27, 2025
Maintains: Buy
Price Target: $32 → $40
Current: $4.30
Upside: +830.23%
Aug 15, 2025
Upgrades: Buy
Price Target: $35
Current: $11.78
Upside: +197.11%
Aug 11, 2025
Maintains: Buy
Price Target: $12 → $8
Current: $0.54
Upside: +1,394.77%
Jul 22, 2025
Maintains: Buy
Price Target: $10 → $9
Current: $4.39
Upside: +105.01%
Jul 7, 2025
Maintains: Buy
Price Target: $40 → $20
Current: $1.48
Upside: +1,251.35%
Jul 1, 2025
Reiterates: Buy
Price Target: $36
Current: $10.85
Upside: +231.80%
Jun 16, 2025
Reiterates: Buy
Price Target: $115
Current: $68.31
Upside: +68.35%
Apr 16, 2025
Maintains: Buy
Price Target: $560 → $280
Current: $9.49
Upside: +2,850.47%
Apr 1, 2025
Reiterates: Buy
Price Target: $8
Current: $2.42
Upside: +230.58%
Mar 31, 2025
Reiterates: Buy
Price Target: $30
Current: $2.66
Upside: +1,027.82%
Mar 27, 2025
Reiterates: Buy
Price Target: $18
Current: $2.22
Upside: +710.81%
Mar 26, 2025
Reiterates: Buy
Price Target: $183
Current: $3.32
Upside: +5,400.30%
Mar 26, 2025
Reiterates: Buy
Price Target: $7
Current: $0.57
Upside: +1,138.94%
Mar 12, 2025
Reiterates: Neutral
Price Target: n/a
Current: $1.37
Upside: -
Nov 15, 2024
Reiterates: Buy
Price Target: $33
Current: $0.60
Upside: +5,363.58%
Apr 25, 2024
Reiterates: Neutral
Price Target: n/a
Current: $3.15
Upside: -